BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hsu SJ, Yu ML, Su CW, Peng CY, Chien RN, Lin HH, Lo GH, Su WW, Kuo HT, Hsu CW, Yang SS, Yang SS, Tseng KC, Qin A, Huang YW, Chuang WL. Ropeginterferon Alfa-2b administered every two weeks for patients with genotype 2 chronic hepatitis C. J Formos Med Assoc 2021;120:956-64. [PMID: 33077341 DOI: 10.1016/j.jfma.2020.09.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Huang YW, Qin A, Fang J, Wang TF, Tsai CW, Lin KC, Teng CL, Larouche R. Novel long-acting ropeginterferon alfa-2b: Pharmacokinetics, pharmacodynamics and safety in a phase I clinical trial. Br J Clin Pharmacol 2021. [PMID: 34907578 DOI: 10.1111/bcp.15176] [Reference Citation Analysis]
2 Chen KY, Lee KY, Qin A, Luo CS, Yeh YK, Zheng JQ, Chen CM, Tsai CY, Lin S, Liao J, Huang YW, Feng PH. Clinical Experience with Ropeginterferon Alfa-2b in the Off-Label Use for the Treatment of COVID-19 Patients in Taiwan. Adv Ther 2022;39:910-22. [PMID: 34910280 DOI: 10.1007/s12325-021-01998-y] [Reference Citation Analysis]
3 Huang YW, Tsai CY, Tsai CW, Wang W, Zhang J, Qin A, Teng C, Song B, Wang MX. Pharmacokinetics and Pharmacodynamics of Novel Long-Acting Ropeginterferon Alfa-2b in Healthy Chinese Subjects. Adv Ther 2021;38:4756-70. [PMID: 34328630 DOI: 10.1007/s12325-021-01863-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 Edahiro Y, Ohishi K, Gotoh A, Takenaka K, Shibayama H, Shimizu T, Usuki K, Shimoda K, Ito M, Vanwart SA, Zagrijtschuk O, Qin A, Kawase H, Miyachi N, Sato T, Komatsu N, Kirito K. Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study. Int J Hematol. [DOI: 10.1007/s12185-022-03341-9] [Reference Citation Analysis]
5 Lin HH, Hsu SJ, Lu SN, Chuang WL, Hsu CW, Chien RN, Yang SS, Su WW, Wu JC, Lee TH, Peng CY, Tseng KC, Qin A, Huang YW, Chen PJ. Ropeginterferon alfa-2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacy. JGH Open 2021;5:929-40. [PMID: 34386602 DOI: 10.1002/jgh3.12613] [Reference Citation Analysis]
6 Huang Y, Qin A, Tsai C, Chen P. Novel Pegylated Interferon for the Treatment of Chronic Viral Hepatitis. Viruses 2022;14:1128. [DOI: 10.3390/v14061128] [Reference Citation Analysis]